A Phase 1 Single Ascending Dose Study of a Recombinant Hyperimmune Polyclonal Antibody Against SARS CoV-2 (GIGA-2050) in Patients Hospitalized With COVID-19
Latest Information Update: 28 Jan 2022
At a glance
- Drugs Recombinant polyclonal antibody therapy - GigaGen (Primary)
- Indications COVID 2019 infections
- Focus Adverse reactions; First in man
- Sponsors GigaGen
- 11 Jan 2022 Status changed from recruiting to discontinued.
- 11 Aug 2021 According to a GigaGen media release, the first patient has been dosed in this trial.
- 04 Jun 2021 Status changed from not yet recruiting to recruiting.
Most Recent Events
Trial Overview
Purpose
to evaluate the safety and tolerability of single ascending IV dose administrations of GIGA-2050 in patients hospitalized with COVID-19.
Comments
Reason the study was stopped: Study stopped for commercial reasons.
Primary Endpoints
Incidence of treatment-emergent adverse events (TEAEs)
description: Frequency of TEAEs graded by the National Cancer Institute (NCI) Common Terminology Criteria for Adverse Events (CTCAE) version 5.0
time_frame: Day 1 up to Day 56
Incidence of treatment-emergent adverse events (TEAEs)
description: Frequency of TEAEs graded by the National Cancer Institute (NCI) Common Terminology Criteria for Adverse Events (CTCAE) version 5.0
time_frame: Day 1 up to Day 56
Change from baseline of vital signs, physical examination, and clinical laboratory assessments
description: Numeric summaries of all observed findings and changes for vital signs, laboratory assessments, physical examinations, and ECG
time_frame: Day 1 up to Day 56
Incidence of infusion-related reactions (IRR) and hypersensitivity reactions
description: Frequency of IRR and hypersensitivity reactions
time_frame: Day 1 through Day 2
Other Endpoints
Pharmacological evaluation of single doses of GIGA-2050
description: Serum titers of antibodies directed against SARS CoV-2 will be measured for the pharmacological profile of single doses of GIGA-2050
time_frame: Day 1 up to Day 28 [1]
Diseases Treated
Indication | Qualifiers | Patient Segments |
---|---|---|
COVID 2019 infections | treatment | - |
Subjects
- Subject Type patients
-
Number
Planned: 18
Actual: 3
- Sex male & female
- Age Group ≥ 18 years; adult
Patient Inclusion Criteria
- Participant is ≥ 18 years of age. - Positive result of a SARS CoV-2 RNA diagnostic test result ≤48 hours before enrollment, warranting hospital admission as per Investigator's judgement. - COVID-19 pneumonia findings on imaging (chest X-ray or CT Scan). - Requires oxygen supplementation with FIO2 approximately 30% or greater administered by nasal cannula, mask, or NIV. - Participants can be on other medication on-label to treat COVID-19 respiratory disease that the Investigator deems clinically relevant in combination with the study drug, including corticosteroids. Passage of 24 hours after administration of the EUA drug will be required prior to dosing GIGA-2050. - Men or non-lactating female participants who are surgically sterile or post-menopausal, or a Woman of Childbearing Potential (WCBP) with a negative pregnancy test at screening willing to use highly effective contraception methods.
Patient Exclusion Criteria
- Acute respiratory failure requiring invasive mechanical ventilation or ECMO at enrollment. - Systolic Blood Pressure (SBP) <110 mmHg or heart rate >120 bpm. - Pre-existing heart failure or unstable angina or myocardial infarction in the last month prior to screening. - Pre-existing chronic respiratory condition(s). - Evidence of acute kidney injury, increase of serum creatinine of ≥1.5 x baseline, or urine output of <0.5mL/kg/hr sustained for at least 6 hours once volume repleted. - Aspartate aminotransferase (AST) ≥2.5 x ULN, alanine aminotransferase (ALT) ≥2.5 x ULN, and/or total bilirubin >1.5 x ULN, or severe hepatic impairment. - Known systemic hypersensitivity to recombinant antibody therapies. - Female participant who is pregnant. - Participant is expected to transfer to a non-investigative facility from the investigation site and cannot be monitored for compliance with protocol-required safety monitoring procedures. - Participants who are currently participating or have participated in another clinical trial within 30 days prior to screening.
Trial Details
Identifiers
Identifier | Owner |
---|---|
NCT04883138 | ClinicalTrials.gov: US National Institutes of Health |
GG-GIGA2050-001 | - |
Organisations
- Sponsors GigaGen
- Affiliations GigaGen
Trial Dates
-
Initiation Dates
Planned : 19 May 2021
Actual : 24 May 2021
-
Primary Completion Dates
Planned : 15 Aug 2021
Actual : 11 Jan 2022
-
End Dates
Planned : 30 Aug 2021
Actual : 11 Jan 2022
Other Details
- Design open; prospective; sequential
- Phase of Trial Phase I
- Location USA
- Focus Adverse reactions; First in man
Interventions
Drugs | Route | Formulation |
---|---|---|
Recombinant polyclonal antibody therapy - GigaGenPrimary Drug | Intravenous | Infusion |
15 mg GIGA-2050 per kg BW
Participants will receive a single IV infusion of 15 mg GIGA-2050 per kg BW, or as determined by SRC review
Drug: GIGA-2050 (Recombinant Hyperimmune Polyclonal Antibody)
5 mg GIGA-2050 per kg BW
Participants will receive a single IV infusion of 5 mg GIGA-2050 per kg BW
Drug: GIGA-2050 (Recombinant Hyperimmune Polyclonal Antibody)
50 mg GIGA-2050 per kg BW
Participants will receive a single IV infusion of 50 mg GIGA-2050 per kg BW, or as determined by SRC review
Drug: GIGA-2050 (Recombinant Hyperimmune Polyclonal Antibody)
Trial Centres
Investigators
Investigator | Centre Name | Trial Centre Country |
---|---|---|
Jennifer Keller
650 268 4255
show details
gigagentrials@gigagen.com |
-
|
|
Sean Liu, MD | Icahn School of Medicine at Mount Sinai | USA |
Centres
Centre Name | Location | Trial Centre Country |
---|---|---|
- |
-
|
-
|
- |
-
|
-
|
GigaGen |
-
|
-
|
Icahn School of Medicine at Mount Sinai | New York, New York | USA |
Trial History
Event Date | Event Type | Comment |
---|---|---|
28 Jan 2022 | Other trial event | Last checked against ClinicalTrials.gov: US National Institutes of Health record. Updated 28 Jan 2022 |
11 Jan 2022 | Status change - discontinued | Status changed from recruiting to discontinued. Updated 28 Jan 2022 |
11 Aug 2021 | Other trial event | According to a GigaGen media release, the first patient has been dosed in this trial. Updated 17 Aug 2021 |
04 Jun 2021 | Status change - recruiting | Status changed from not yet recruiting to recruiting. Updated 09 Jun 2021 |
17 May 2021 | Other trial event | New source identified and integrated (NCT04883138) Updated 09 Jun 2021 |
10 May 2021 | Status change - not yet recruiting | Status changed from planning to not yet recruiting. Updated 17 May 2021 |
15 Apr 2021 | Other trial event | According to a GigaGen media release, this program recently received an IND approval to initiate this study. Updated 16 Apr 2021 |
09 Mar 2021 | Other trial event | According to a GigaGen media release, this trial is expected to start in spring 2021. Updated 16 Mar 2021 |
09 Apr 2020 | New trial record | New trial record Updated 09 Apr 2020 |
30 Mar 2020 | Other trial event | According to a GigaGen media release,company expects to initiate trial in early 2021. Updated 09 Apr 2020 |
References
-
ClinicalTrials.gov: US National Institutes of Health. Trial-Reg 2023;.
Available from: URL: http://clinicaltrials.gov -
GigaGen. GigaGen Initiates Development of Recombinant Polyclonal Antibody Therapy for COVID-19. Media-Rel 2020;.
Media Release -
GigaGen. GigaGen Publishes Research on Companys Recombinant Hyperimmunes in Nature Biotechnology. Media-Rel 2021;.
Media Release -
Grifols. Grifols reinforces its innovation strategy after completing the acquisition of GigaGen to boost a novel method to generate a wide range of immunoglobulins. Media-Rel 2021;.
Media Release -
GigaGen. GigaGen Doses First Patient in Phase 1 Trial of Recombinant Hyperimmune Polyclonal Antibody GIGA-2050 for COVID-19. Media-Rel 2021;.
Media Release
Adis International Ltd. Part of Springer Science+Business Media
© Springer Nature Switzerland AG